Bloomberg Law’s combination of innovative analytics, research tools and practical guidance provides you with everything you need to be a successful litigator.
Some 845 plaintiffs in the federal Levaquin multidistrict litigation have reached settlements with manufacturer Johnson & Johnson over alleged personal injury claims, according to an Oct. 30 filing in the proceedings (Levaquin Products Liability Litigation, In re, D. Minn., No. 08-1943, status report filed 10/30/12).
Plaintiffs sued Johnson & Johnson and subsidiary Ortho-McNeil Janssen Pharmaceuticals Inc., alleging the antibiotic causes tendon rupture. Federal suits were consolidated in the U.S. District Court for the District of Minnesota in 2008.
Settlement is proceeding in several groups, an Oct. 30 status conference report said. The first group involves about 845 plaintiffs, represented by a small number of firms, who reached a settlement in September. The plaintiffs anticipate the agreement will be finalized in the next two weeks, the report said.
The second settlement group involves about 130 plaintiffs, represented by other firms, who are interested in participating in the settlement reached by the first group.
A third group involves plaintiffs represented by counsel who have a small number of cases in the MDL. This group also includes plaintiffs who are not working through MDL counsel, but have reached out directly to defendants to discuss settlement options. Some 60 plaintiffs are involved in the third group, the report said.
The terms of the settlements are confidential, plaintiffs' attorney Ronald Goldser of Zimmerman Reed told BNA Nov. 6.
The parties also are working toward developing a standardized settlement protocol, the report said.
There are 1,793 cases in the federal MDL, according to a Sept. 5 statistics report. The status conference report is at http://op.bna.com/pslr.nsf/r?Open=jstg-8znpc3.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)